The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | Managing problems in treating CLL
Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK gives an overview of her talk ‘How I manage difficult problems in CLL’ at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Chemoimmunotherapy is a common treatment for chronic lymphocytic leukemia (CLL), however, some patients are not fit for chemotherapy. She describes a case where the patient presented with pancytopenia and a TP53 abnormality, that was treated with ibrutinib. Some patients, however relapse from ibrutinib therapy, for multiple reasons. These patients can be treated with more novel agents, such as venetoclax. The role of transplantation in treating CLL discussed, as well as the role of idelalisib and rituximab and the prevention of infection related side effects. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
